Takeda Pharmaceutical (NYSE:TAK) Announces Earnings Results, Beats Expectations By $0.31 EPS

Takeda Pharmaceutical (NYSE:TAK) issued its quarterly earnings results on Thursday. The company reported $0.48 earnings per share for the quarter, topping the consensus estimate of $0.17 by $0.31, Zacks reports. The company had revenue of $7.50 billion for the quarter, compared to the consensus estimate of $7.13 billion. Takeda Pharmaceutical had a net margin of 4.31% and a return on equity of 11.20%. Takeda Pharmaceutical updated its FY 2026 guidance to 3.009-3.009 EPS.

Here are the key takeaways from Takeda Pharmaceutical’s conference call:

• Q1 results were broadly on plan: Core revenue declined 0.5% and core operating profit fell 0.5% at constant exchange rates, while core EPS decreased 11.8% to JPY 154 due largely to an unfavorable comparison with the prior year’s tax benefit. Full-year guidance, including JPY 650–750 billion of free cash flow, was maintained.
• The company reported continued resilience in its established portfolio, with core inline brands growing 2.3% at constant exchange rates. ENTYVIO grew 4%, new launches increased 22.6%, and transformation savings are intended to fund investments in upcoming products and the late-stage pipeline.
• Takeda is preparing for a potentially significant launch cycle, with ORZEYFUL for narcolepsy type 1 and rusfertide for polycythemia vera expected to launch in the U.S. in the second half of 2026, followed by zasocitinib for psoriasis in the first half of 2027. ORZEYFUL has already received its first approval in China, while rusfertide has received FDA priority review.
• Zasocitinib produced encouraging phase III psoriasis results, demonstrating statistical superiority to deucravacitinib across primary and key secondary endpoints, with more than 35% of patients achieving complete skin clearance at week 16. Management also highlighted promising data in difficult-to-treat areas and additional development opportunities in inflammatory bowel disease and other immune-mediated conditions.
• Near-term financial performance remains pressured by mature-product erosion, including continued generic competition for Vyvanse, while operating cash flow was lower because of working-capital effects and free cash flow included a $200 million payment to Protagonist related to rusfertide rights. ENTYVIO biosimilar litigation is expected to take roughly three to five years, with U.S. entry timing still broadly anticipated around 2032.

Takeda Pharmaceutical Stock Performance

Shares of TAK traded down $0.11 during trading hours on Friday, hitting $17.14. The stock had a trading volume of 2,885,406 shares, compared to its average volume of 3,138,680. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.60 and a current ratio of 1.09. The firm has a 50-day moving average price of $16.25 and a 200 day moving average price of $17.07. Takeda Pharmaceutical has a fifty-two week low of $12.99 and a fifty-two week high of $18.90. The firm has a market capitalization of $54.91 billion, a price-to-earnings ratio of 43.96 and a beta of -0.07.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Sivia Capital Partners LLC purchased a new stake in shares of Takeda Pharmaceutical during the 2nd quarter worth about $351,000. Glenmede Investment Management LP increased its stake in shares of Takeda Pharmaceutical by 12.4% in the 3rd quarter. Glenmede Investment Management LP now owns 34,677 shares of the company’s stock valued at $508,000 after purchasing an additional 3,824 shares in the last quarter. &PARTNERS increased its stake in shares of Takeda Pharmaceutical by 9.8% in the 4th quarter. &PARTNERS now owns 28,629 shares of the company’s stock valued at $446,000 after purchasing an additional 2,554 shares in the last quarter. Smartleaf Asset Management LLC raised its holdings in Takeda Pharmaceutical by 24.5% in the 4th quarter. Smartleaf Asset Management LLC now owns 24,772 shares of the company’s stock worth $387,000 after purchasing an additional 4,877 shares during the period. Finally, Equitable Holdings Inc. acquired a new position in Takeda Pharmaceutical in the 3rd quarter worth about $285,000. Hedge funds and other institutional investors own 9.17% of the company’s stock.

Analyst Ratings Changes

TAK has been the subject of a number of research reports. Wall Street Zen upgraded shares of Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Saturday, July 18th. Weiss Ratings downgraded Takeda Pharmaceutical from a “hold (c)” rating to a “hold (c-)” rating in a research report on Tuesday, June 23rd. Zacks Research lowered Takeda Pharmaceutical from a “hold” rating to a “strong sell” rating in a research note on Monday, June 29th. Finally, Sanford C. Bernstein raised Takeda Pharmaceutical from a “market perform” rating to an “outperform” rating in a report on Wednesday, April 8th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Takeda Pharmaceutical presently has a consensus rating of “Hold”.

Key Headlines Impacting Takeda Pharmaceutical

Here are the key news stories impacting Takeda Pharmaceutical this week:

• Positive Sentiment: Takeda reported fiscal first-quarter adjusted earnings of $0.48 per share, well above the $0.17 analyst consensus, while revenue rose to $7.50 billion versus expectations of $7.13 billion. The results reflect resilient performance from the company’s core portfolio. Takeda Pharmaceutical Fiscal Q1 Core Earnings, Revenue Rise
• Positive Sentiment: Takeda issued fiscal 2026 guidance for approximately $29.6 billion in revenue and $3.009 in EPS, above analyst expectations of roughly $29.0 billion and $1.57, respectively. The outlook supports the investment case, although the unusually precise EPS figure may reflect a reporting or formatting issue. Takeda Fiscal 2026 Guidance
• Positive Sentiment: Bank of America Securities analyst Koichi Mamegano reiterated a Buy rating and maintained his price target, citing the first-quarter beat and continued progress across Takeda’s development pipeline. Bank of America Reiterates Buy Rating
• Neutral Sentiment: Takeda will pay Keros Therapeutics a $20 million development milestone under their collaboration, signaling advancement of the partnered program but also representing near-term development spending. Keros Therapeutics Milestone Payment
• Neutral Sentiment: A UK Patents Court ruling imposed an extended prosecution bar in litigation involving Fresenius Kabi and Millennium Pharmaceuticals, a Takeda subsidiary. The immediate financial impact on Takeda is unclear. Patents Court Ruling
• Negative Sentiment: Takeda discontinued another Phase 2 therapy for celiac disease, leaving only one candidate in that area. The decision narrows the pipeline and increases reliance on the remaining program, weighing on longer-term growth expectations. Takeda Celiac Disease Program Discontinued

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.